Abstract:OBJECTIVE:To compare the CC-chemokine ligand 18 (CCL18) expression in the serum and malignant pleural effusion (MPE) of NSCLC patients and explore its regulatory effect on differentiation of monocyte-derived dendritic cells (Mo-DC).METHODS:CCL18 levels in the serum and MPE from 62 NSCLC patients were quantitated by immunoassay. CCL18 in sera from 26 healthy individuals, 28 exudative pleural effusions from inflammatory pulmonary diseases and 17 transudative pleural effusions from non-inflammatory diseases were used as control. Mo-DC was generated by culturing NSCLC-derived monocytes with GM-CSF and IL-4 in the presence or absence of CCL18. The mean fluorescent intensity (MFI) of CD14, CD80, CD83, CD86 and HLA-DR were analyzed by flow cytometry (FCM). Mo-DC was then co-cultured with purified T cells and the percence of CD25(+)FoxP3(+) cells was assayed by FCM.RESULTS:CCL18 levels in the sera of NSCLC patients and healthy individuals were (132.70 ± 15.52) ng/ml and (18.44 ± 0.99) ng/ml, respectively (P < 0.001). The levels of CCL18 in MPE, exudative PE and transudative PE were (155.6 ± 13.58) ng/ml, (190.4 ± 22.33) ng/ml and (20.89 ± 3.03) ng/ml, respectively. CCL18 in the MPE was significantly higher than that in transudates (P < 0.001), however, no significant difference was observed between CCL18 expression in exudative PE and MPE (P = 0.172). Of note, a moderate positive correlation (r = 0.421, P < 0.01) was observed between CCL18 levels in the paired MPE and serum of NSCLC. In the healthy control group, Mo-DC cultured in the presence of CCL18 showed 31.4 ± 15.8 (MFI) of CD14 expression, which was significantly higher than that in Mo-DC cultured in the absence of CCL18 (18.5 ± 8.9, P < 0.05). In contrast, the expressions of MFI of CD80, CD83, CD86 and HLA-DR were significantly decreased upon CCL18 induction (P < 0.05). In the NSCLC group, GM-CSF+IL-4+CCL18 induced a MFI of 45.2 ± 13.8 of CD14 expression in Mo-DC, which was also significantly higher than that of GM-CSF+ IL-4 induction (22.6 ± 10.5, P < 0.01). Similarly, the expressions of MFI of CD80, CD83, CD86 and HLA-DR were significantly decreased in the presence of CCL18 (P < 0.05). Furthermore, the MFI of CD14, CD83, CD86 and HLA-DR had significant differences between GM-CSF/IL-4/CCL18-induced Mo-DC derived from NSCLC patients and healthy control (P < 0.05). Finally, CD4(+) T cells co-cultured with NSCLC-derived, GM-CSF/IL-4/CCL18-treated Mo-DC had significantly higher percent of CD25(+)FoxP3(+) cells compared with that of CD4(+) T cells stimulated with Mo-DC induced by GM-CSF/IL-4(P < 0.01).CONCLUSIONS:CCL18 is present at a high level in MPE and serum of NSCLC patients complicated with pleural effusion and a moderate positive correlation exists between CCL18 levels in the two fluids. CCL18 inhibits maturation of Mo-DC, which consequently stimulates T cells to differentiate into CD25(+)FoxP3(+) regulatory T cells.

The differentiation of new human CD303+ Plasmacytoid dendritic cell subpopulations expressing CD205 and/or CD103 regulated by Non-Small-Cell lung cancer cells

Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c+ Conventional Dendritic Cell Subsets Mediated by CD103 and CD205

Differential Requirements for CD4+ T Cells in the Efficacy of the Anti-Pd-1+lag-3 and Anti-Pd-1+ctla-4 Combinations in Melanoma Flank and Brain Metastasis Models.

The change of proportion and inhibition on CD8~+T lymphocytes of myeloid-derived suppressor cells in peripheral blood from patients with non-small cell lung cancer

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Elevated Circulating CD4(+)CD25(-)Foxp3(+) Regulatory T Cells in Patients with Nonsmall Cell Lung Cancer

Expression of CC-chemokine Ligand 18 (CCL18) in the Serum and Pleural Effusion of Non-Small-cell Lung Cancer Patients and Its Regulatory Effect on the Differentiation of Monocyte-Derived Dendritic Cells

Functionally Impaired Follicular Helper T Cells Induce Regulatory B Cells and CD14(+) Human Leukocyte Antigen-Dr- Cell Differentiation in Non-Small Cell Lung Cancer

A Novel Subset of B7-H3+CD14+HLA-DR−/lowmyeloid-derived Suppressor Cells Are Associated with Progression of Human NSCLC

The Prevalence of FOXP3+ Regulatory T-Cells in Peripheral Blood of Patients with NSCLC

Clinical Significance of the Induction of Macrophage Differentiation by the Costimulatory Molecule B7-H3 in Human Non-Small Cell Lung Cancer.

Study on the CD4+CD25+FoxP3+ Regulatory Cells in Peripheral Blood of NSCLC Patients

The variation of CD4 + CD25 + regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer

Insufficient CD100 shedding contributes to suppression of CD8+ T-cell activity in non-small cell lung cancer

CD13+CD4+CD25hiregulatory T Cells Exhibit Higher Suppressive Function and Increase with Tumor Stage in Non-Small Cell Lung Cancer Patients

Expression and significance of CD4+CD25high regulatory T cells in patients with non-small-cell lung cancer

Analyzing the Percentage of Different PD-1+ T Cell Subsets in Peripheral Blood and Bronchoalveolar Lavage Fluid of Small Cell Lung Cancer Patients: A Prospective Study.

Effect of dendritic cell immunotherapy on distribution of dendritic cell subsets in non-small cell lung cancer

Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients

CD300ld on neutrophils is required for tumour-driven immune suppression